Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary.

Lycke, Jan; Svenningsson, Anders

Lycke, Jan; Svenningsson, Anders.

Lycke J; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Svenningsson A; Department of Clinical Sciences and Department of Neurology, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

Mult Scler ; 28(8): 1177-1178, 2022 07.

Article in English | MEDLINE | ID: covidwho-1902302

Subject(s)

Antibodies, Monoclonal; Antineoplastic Agents; Antibodies, Monoclonal/therapeutic use; Antigens, CD20; Humans; Rituximab/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic study Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585221101138

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google